Ascendia

  MARKET NEWS

 

Sermonix Pharmaceuticals Announces Breast Cancer Research Examining Lasofoxifene’s Preclinical Effects on Aromatase Inhibitor Resistant Non-ESR1 Mutated Breast Cancer
Kyowa Kirin Announces Board Approval for Construction of New Biologics Manufacturing Plant in Sanford, NC
SiSaf’s Bio-Courier Technology Enables Clinical Trial Success for Topical Treatment of Mild-to-Moderate Alopecia Areata
Assembly Biosciences Doses First Participant in Phase 1a/b Clinical Trial of Herpes Simplex Virus Helicase-Primase Inhibitor Candidate
MoonLake Immunotherapeutics Announces Positive Regulatory Feedback From Both FDA & EMA
Atriva Therapeutics Secures US Patent for First-in-Class Broad Spectrum Therapy for Severe RNA Virus Infections Including Bird Flu

  FEATURED EDITORIAL

  COMPANY PROFILE

Cayman Chemical has been supplying high-purity lipids to the scientific community for more than 40 years. Our industry-leading expertise in lipid chemistry, synthesis, and purification is supported by state-of-the-art analytical equipment. We are committed to offering an unprecedented portfolio of lipid nanoparticle research toolsto support research and development. Our portfolio includes an impressive collection of ready-to-use and custom lipids for LNPs including ionizable cationic lipids, helper lipids, sterol lipids, and PEGylated lipids. We also offer research-ready LNPs to screen different LNP compositions and provide in-house lipid synthesis, screening, and LNP development services. Click here for more.

  EXCLUSIVE ONLINE CONTENT

Spherix Global Insights Expands Therapeutic Area Coverage Into Hematology

Spherix Global Insights Expands Therapeutic Area Coverage Into Hematology

Spherix diversifies portfolio with strategic entry into classical hematology, tapping into a specialty with a high unmet patient need and expansive market growth…..

CordenPharma & Certest: A Powerful Partnership Unleashing the Potential of Patented Ionizable Lipids in LNP Formulation

CordenPharma & Certest: A Powerful Partnership Unleashing the Potential of Patented Ionizable Lipids in LNP Formulation

CordenPharma and Certest have signed a partnership agreement on May 7, 2024, which aims to add ionizable lipids to CordenPharma’s complex LNP formulation services, the missing….

Vetter Announces Plans to Expand its Capacity in the US & Germany

Vetter Announces Plans to Expand its Capacity in the US & Germany

The move will effectively double the capacity of Vetter Development Services in the US and provide ample space for future expansion opportunities…..

Gerresheimer to Acquire Blitz LuxCo Sarl, the Holding Company of the Bormioli Pharma Group 

Gerresheimer to Acquire Blitz LuxCo Sarl, the Holding Company of the Bormioli Pharma Group 

Gerresheimer underpins leading market position as a full-service provider for the pharmaceutical and biotech industries….

  WHITEPAPERS & WEBINARS

WHITEPAPER - PLGA Nanoparticles - Bridging the Gap From R&D to GMP

WHITEPAPER - PLGA Nanoparticles - Bridging the Gap From R&D to GMP

Poly(lactic-co-glycolic acid) (PLGA) has emerged as a promising material for drug delivery and biomedical applications. Its exceptional biocompatibility, customizable degradation and release properties, and versatility have led to its approval by regulatory bodies like the FDA and EMA.…

WHITEPAPER - Continuous Flow - An Emerging Alternative

WHITEPAPER - Continuous Flow - An Emerging Alternative

Pharmaceutical companies have traditionally been risk-averse, often adopting safe and well-established processes due to the conservative stance of regulatory agencies on novel methodologies. However, with the increasing complexity of drug molecules and the demand for newer and harsher reaction conditions, …

WHITEPAPER - Overcoming the Knowledge Gap: Long-Acting Injectables & Implantables

WHITEPAPER - Overcoming the Knowledge Gap: Long-Acting Injectables & Implantables

What’s In This Whitepaper?

Long-acting products, such as Long-Acting Injectables (LAIs) and implantables, have gained significant traction in recent years, revolutionizing patient treatment and medication adherence. By reducing the number of doses required, long-acting products improve patient compliance and eliminate …

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

June 19 – Bioavailability
June 26 – Excipients